Randomized Controlled Trial to Assess Blockade of Voltage Gated Sodium Channels During Surgery in Operable Breast Cancer
NCT01916317 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1600
Last updated 2025-04-09
Summary
Voltage Gated Sodium Channels Over the years, there is more evidence that ionic channels are involved in the oncogenic process. Among these, voltage gated sodium channels (VGSC) expressed in non-nervous or non-muscular organs are often associated with the metastatic behavior of different cancers.
Expression of VGSCs has been reported both in vitro and/or in vivo in a range of human carcinomas, including breast cancer Ion channels are major signaling molecules expressed in a wide variety of tissues. They are involved in determining a variety of cellular functions like proliferation, solute transport, volume control, enzyme activity, secretion, invasion, gene-expression, excitation-contraction coupling, and intercellular communication.4 VGSC activity contributes to much cellular behavior integral to metastasis, including cellular process extension, lateral motility and galvanotaxis, transverse invasion, and secretory membrane activity.
A correlation between Na transport and oncogenesis has been widely reported in literature. In 1980, transformed mouse mammary cells were shown to have 3-fold higher intra-cellular sodium content than untransformed cells.5 Additionally evidence suggest that increasing the inward sodium current through voltage gated sodium channels increased the invasive capacity of breast cancer.6 Also, growth and proliferation of mammary adenocarcinoma cells can be inhibited by Amiloride suggesting that epithelial Na channels (ENaC) activity is correlated with proliferation of breast cancer cells
Current evidence suggests that VGSC activity is necessary and sufficient for cancer cell invasiveness8. A recent in vitro study has shown that the human MDA MB 231 breast cancer cell line expressed functional VGSCs9. However, the molecular nature of the VGSC and its functional relevance to breast cancer in vivo are currently under study.
Surgical operations for cancer have been reported to induce dissemination of cancer cells into surrounding tissues or into the circulation10,11and infiltration anesthetics can inhibit immune response12-14. Although the mechanism remains to be elucidated, infiltration anesthetics such as lidocaine have membrane- stabilizing action (Seeman, 1972) and these agents could have direct effects on cancer cells. Therefore, it is important to clarify the effects of infiltration anesthetics on behavior of the tumor cells.
Commonly used local anesthetic agents inhibit the VGSCs and also possess a unique membrane stabilizing action through other unknown mechanisms. A study by Mammota et al 15 reported that lignocaine, effectively inhibited the invasive ability of human cancer (HT1080, HOS, and RPMI-7951) cells at concentrations used in surgical operations (5-20 mM). Lidocaine reduced the invasion ability of these cells by partly inhibiting the shedding of HB-EGF from the cell surface and modulation of intracellular Ca2+ concentration contributed to this action. In addition, lidocaine (5-30 mM) infiltrated around the inoculation site, inhibited pulmonary metastases of murine osteosarcoma (LM 8) cells in vivo.
Dose of lidocaine15:
40 mM (1%) lidocaine is usually used for infiltration anesthesia for surgical operations. Lower concentrations (1-20mM) of lidocaine were sufficient to suppress the invasive ability of cancer cells14. One mM lidocaine inhibited the invasive ability of HT1080 cells by about 50%, and 20 mM lidocaine inhibited the invasion ability completely. Lidocaine also inhibited dose-dependently the invasive ability of HOS and RPMI-7951 cells, although it was less effective on HOS cells. Lignocaine exerts its anesthetic action by obstructing the sodium channel 16 however, 10 mMof tetrodotoxin (TTX), a specific sodium channel inhibitor, had little effect on the invasive ability of HT1080 cells. Ten mM lidocaine-N-ethylbromide (NEB), which does not cross the cell membrane, also had little effect on the invasive ability of the cells.
Objectives
Primary Objective:
• To assess the in-vivo ability of local anesthetics agents like lignocaine to decrease the dissemination of cancer cells during surgery and improve the disease free interval
Secondary Objective
• To assess the in-vivo ability of local anesthetics agents like lignocaine on impacting long term survival.
Methodology / Treatment plan
The study drug (0.5% lidocaine 60mM) will be tested in the intraoperative setting prior to surgery will be tested in a randomized setting.:
Arm A: 60mM of 0.5% lignocaine will be injected peritumoral prior to excision. The local anesthetic should be injected on all 6 surfaces of the tumor and also within the tumor. Wait for 7 minutes for its action followed by surgery. (Intervention arm) Arm B: No injection of lignocaine prior to excision (Control arm)
Conditions
- Operable Breast Cancer
Interventions
- DRUG
-
0.5% lignocaine 60mM
Sponsors & Collaborators
-
Shri Siddhivinayak Ganpati Cancer Hospital
collaborator UNKNOWN -
Kolhapur Cancer Centre (KCC)
collaborator UNKNOWN -
Max Super Speciality Hospital
collaborator OTHER -
Basavatarakam Indo American Cancer Hospital & Research Institute
collaborator OTHER -
Malabar Cancer Centre (MCC)
collaborator UNKNOWN -
North Eastern Indira Gandhi Regional Institute of Health and Medical Sciences (NEIGRIHMS)
collaborator UNKNOWN -
All India Institute of Medical Sciences
collaborator OTHER -
Gujarat Cancer & Research Institute
collaborator OTHER -
Sterling Multi Speciality Hospital (SMSH)
collaborator UNKNOWN -
Dr. B Barooha Cancer Institute (BBCI)
collaborator UNKNOWN -
Tata Memorial Hospital
lead OTHER_GOV
Principal Investigators
-
Rajendra A Badwe, MS · Director and professor, Surgical Oncology
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 99 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2011-12-12
- Primary Completion
- 2026-10-31
- Completion
- 2026-12-31
Countries
- India
Study Locations
More Related Trials
-
Effects of Magnesium Sulfate on Onset and Duration of Low Dose Rocuronium
NCT02100293 ·Status: COMPLETED ·Phase: NA
-
Effect of Amobarbital Sodium Combined With Low-dose Propofol on Hemodynamics During Induction and Perioperative Adverse Reactions
NCT06385756 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Synergistic Effect of Intravenous Lidocaine on Anesthetic Induction and Emergence in Patients Undergoing Laparoscopic Cholecystectomy or Gynecological Surgery
NCT07193836 ·Status: ENROLLING_BY_INVITATION ·Phase: NA
-
The Effect of Total Intravenous Anesthesia and Volatile Anesthesia on Shedding of the Endothelial Glycocalyx in Patients Undergoing Laparoscopic or Robotic Assisted Gastrectomy
NCT04183296 ·Status: COMPLETED ·Phase: NA
-
Perioperative Magnesium Sulphate as a Cerebral Protector in Neurosurgical Patients
NCT01601314 ·Status: COMPLETED ·Phase: PHASE3
-
Comparison of Ropivacaine-Poloxamer 407 Hydrogel and TAP Block for Postoperative Pain Management in Laparoscopic/Robotic Gastrectomy
NCT06839716 ·Status: RECRUITING ·Phase: NA
-
Ropivacaine-Poloxamer 407 Gel for Pain Control After Open Gastrectomy
NCT06778954 ·Status: RECRUITING ·Phase: NA
-
Combined Use of Etomidate and Propofol in Painless Gastroscopy.
NCT01913054 ·Status: UNKNOWN ·Phase: PHASE4
-
Comparison Between IT Fentanyl and IV Granisetron in Prevention of Vomiting in CS Under Spinal Anesthesia
NCT05474001 ·Status: UNKNOWN ·Phase: NA
-
Study on the Level of Neuromuscular Blockade
NCT03782233 ·Status: COMPLETED ·Phase: NA
-
Deep vs Moderate Neuromuscular Blocks on Remifentanil for Laparoscopic Gastrectomy
NCT04205097 ·Status: COMPLETED ·Phase: NA
-
Effect of Anesthetic Agents on Optic Nerve Sheath Diameter
NCT03701529 ·Status: COMPLETED ·Phase: NA
-
Comparison of Rocuronium Induced Neuromuscular Blockade in Late Second Trimester Pregnant and Non-pregnant Women
NCT04253093 ·Status: UNKNOWN
-
Effect of Intraoperative Anesthetic Management on Postoperative Nausea and Vomiting in Bariatric Surgery
NCT01449708 ·Status: COMPLETED ·Phase: PHASE4
-
Sugammadex-Induced Clenching During Neuromuscular Blockade Reversal
NCT06962007 ·Status: COMPLETED ·Phase: NA
-
Reversal of Neuromuscular Blockade and Perioperative Arrhythmias
NCT04720573 ·Status: COMPLETED ·Phase: NA
-
Comparison Between Drugs for Control of Emetic Attacks During Caesarean Delivery
NCT06300346 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Preoperative Oral Carbohydrate for Nausea and Vomiting Prevention During Cesarian Section
NCT04069806 ·Status: UNKNOWN ·Phase: NA
-
Valproic Acid, Magnesium Sulphate, Rocuronium Requirement, Postoperative Analgesia
NCT01460563 ·Status: UNKNOWN ·Phase: NA
-
The Effect of Deep Neuromuscular Blockade on Requirement of Intravenous Anesthetic Agent
NCT03890406 ·Status: COMPLETED ·Phase: NA
-
Glycopyrrolate Prophylaxis for Prevention of Bradyarrhythmia During Laparoscopic Cholecystectomy
NCT05997004 ·Status: COMPLETED ·Phase: NA
-
Granisetron Versus Ondansetron: Comparative Effects on ECG, QTc
NCT01352130 ·Status: COMPLETED ·Phase: PHASE4
-
Comparison of Remimazolam and Midazolam for Preventing Intraoperative Nausea and Vomiting During Cesarean Section Under Spinal Anesthesia
NCT05736341 ·Status: COMPLETED ·Phase: NA
-
Pharmacokinetics of Sugammadex in Reversal of Vecuronium-induced Neuromuscular Blockade in Patients During Laparoscopic Surgery
NCT05328778 ·Status: COMPLETED ·Phase: PHASE4
-
Effects of an Oral Multi-vitamin Carbohydrate Beverage on Intraoperative Nausea and Vomiting
NCT06333626 ·Status: NOT_YET_RECRUITING ·Phase: NA